VBI Vaccines Inc. (NASDAQ:$VBIV), a biopharmaceutical company headquartered in Cambridge, MA, announced today that VBI’s President and CEO, Jeff Baxter, will be presenting at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 12:30 PM ET in New York City.
For those unable to make the conference, there will be a live audio webcast starting at 12:30 ET on http://wsw.com/webcast/jeff105/vbiv
To guarantee timely access, VBI suggests that individuals register for the webcast at least 10 minutes before the presentation starts. Following the event, there will be a replay of the webcast for 90 straight days on the VBI website.
Details of the Conference
-
Conference: Jefferies 2017 Global Healthcare Conference
-
Date and Time: Friday, June 9, 2017 at 12:30 PM Eastern Time
-
Webcast link: http://wsw.com/webcast/jeff105/vbiv
A Brief Overview: VBI Vaccines Inc.
As mentioned, VBI Vaccines Inc is a biopharmaceutical company. They specialize in the development of vaccines which are meant to address needs that have not been met in infectious disease and immuno-oncology. VBI’s first product, known as Sci-B-Vac™, has been approved for use in Israel and 14 other countries. Sci-B-Vac™ is a hepatitis B vaccine that has the ability to mimic all three viral surface antigens of the HBV virus. Additionally, VBI has eVLP Platform technology which authorizes the development of enveloped virus-like particle vaccines which mirror the target virus to evoke a potent immune response.
Furthermore, VBI is working on advancing a pipeline of eVLP vaccines and they are advancing their LPV™ Thermostability Platform. This platform is a proprietary process which allows for vaccines and biologics to have stability, potency, and safety.
As previously mentioned, VBI Vaccines is headquartered in Cambridge, MA, but they also have numerous research operations in Ottawa, Canada and manufacturing facilities in Rehovot, Israel.
Featured Image: facebook.com
